# Eledon Pharmaceuticals

Organization · id `cardio:org-eledon-pharmaceuticals` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov sponsor names](<https://clinicaltrials.gov/search?spons=Eledon+Pharmaceuticals>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 3 trials in this atlas.

## Technical summary

Sponsor class industry. No ROR record matches the name exactly.

## The registry's words

- Sponsor name: Eledon Pharmaceuticals
- Sponsor class: INDUSTRY

## Connected pages

- Sponsors: Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation (`cardio:ct-nct05983770`)
- Sponsors: Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients (`cardio:ct-nct06126380`)
- Sponsors: Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation (`cardio:ct-nct07835581`)

## Provenance

Content hash: 9540b4419bfbed2a2afadd3b84b94c488858f4c954a5056a011198f28fe47b13
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
